The Effects of Gonadotropin Releasing Hormone Analogue Therapy on Girls with Gonadotropin-dependent Precocious Puberty
|
|
- Beverly Lang
- 5 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE The Effects of Gonadotropin Releasing Hormone Analogue Therapy on Girls with Gonadotropin-dependent Precocious Puberty Yi-Ching Tung, Jing-Sheng Lee, Wen-Yu Tsai, Pei-Hung Hsiao Background/Purpose: It has been reported that gonadotropin releasing hormone analogue (GnRHa) therapy can improve the adult height of patients with gonadotropin-dependent precocious puberty. The purpose of this study was to evaluate the effect of GnRHa on the adult height of girls with gonadotropindependent precocious puberty and the adverse effects of such therapy. Methods: Between 1989 and 2006, 11 girls with gonadotropin-dependent precocious puberty who had been treated with GnRHa and reached their adult height were enrolled in the present study. Follow-up studies of bone age, pelvic sonography and GnRH test were done regularly during the period of treatment. All patients had bone mineral density examined at least 2 years after completion of GnRHa therapy. Results: GnRHa therapy was initiated at the age of 8.0 ± 1.5 years. The predicted adult height immediately before GnRHa therapy was ± 4.8 cm ( 2.3 ± 0.9 standard deviation [SD]). The duration of GnRHa therapy was 4.7 ± 1.8 years. The adult height of the patients was ± 4.3 cm ( 0.6 ± 0.8 SD), which is similar to their target height of ± 4.5 cm ( 0.5 ± 0.8 SD). The uterine sizes and gonadotropin responses to GnRH stimulation were well suppressed during treatment. Menstruation resumed 9.2 ± 5.9 months after the discontinuation of treatment in these patients. Forty-five percent of patients had lumbar bone mineral density less than 1 SD below that of normal young Taiwanese adults in the Taipei region. Conclusion: GnRHa therapy can improve the adult height of patients with gonadotropin-dependent precocious puberty. However, 45% of patients had decreased bone accretion during therapy. [J Formos Med Assoc 2007;106(10): ] Key Words: bone mineral density, GnRH analogue, precocious puberty Precocious puberty is usually defined as the appearance of secondary sexual characteristics before the age of 8 years in girls and 9 years in boys. 1 Gonadotropin-dependent precocious puberty, also known as central precocious puberty (CPP), is caused by the premature activation of gonadotropin releasing hormone (GnRH) pulse generator in the hypothalamus. 2 It may be caused by intracranial organic lesions such as hamartoma, hydrocephalus and infection, or occur without obvious lesion. Patients with CPP usually have acceleration of the tempo of puberty and bone age maturation resulting in early fusion of epiphyseal growth plates and short adult height. 3 Synthetic GnRH analogues (GnRHa) have been introduced as suppressive therapy for CPP since Continuous administration of GnRH will downregulate the GnRH receptors of the pituitary 2007 Elsevier & Formosan Medical Association Department of Pediatrics, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan. Received: March 20, 2007 Revised: April 17, 2007 Accepted: June 5, 2007 Correspondence to: Dr Wen-Yu Tsai, Department of Pediatrics, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 100, Taiwan. wenyutsai@ntu.edu.tw 826 J Formos Med Assoc 2007 Vol 106 No 10
2 GnRHa therapy in central precocious puberty gland and desensitize the pituitary response to GnRH, resulting in suppression of the secretion of downstream gonadotropins and sex hormones. 5 There is some evidence that suppression of the abnormal progression of puberty in patients with CPP can prolong the period of growth in these children and improve their adult height. 6,7 There has been concern about the side effects of long-term GnRHa therapy in children. 8 The recovery of the hypothalamus pituitary gonad axis and resumption of menstruation has been demonstrated. 9,10 However, the effect on bone mineral density (BMD) is still inconclusive. 11,12 Our study aimed to evaluate the efficacy of longterm GnRHa therapy and its possible adverse effects in Taiwanese girls with CPP. Materials and Methods Subjects Between 1989 and 2006 at the pediatric endocrine clinic of National Taiwan University Hospital, there were 13 girls with CPP who had been treated with GnRHa and who reached their adult height. Two of them who had been treated with GnRHa and growth hormone because of the coexistence of growth hormone deficiency were excluded. Thus, 11 girls were enrolled for evaluation in the present study. The etiologies of the 11 patients were as follows: three had hypothalamic hamartoma, one had post-traumatic hydrocephalus, and seven were classified as idiopathic. There was no statistically significant difference in the auxological data before treatment between these two groups except that the patients with central nervous system lesion had their onset of puberty at a younger age than those with idiopathic CPP (3.9 ± 1.7 years vs. 6.0 ± 2.4 years). Therefore, their data were grouped together in the discussion. The 11 girls started GnRHa therapy at the age of 8.0 ± 1.5 years. All of the patients had demonstrated that their gonadotropin levels were responsive to GnRH stimulation before treatment, which was considered the criterion for the confirmation of their gonadotropin dependence. Their bone age at the start of treatment was 11.5 ± 1.3 years, which was advanced more than 2 standard deviations (SDs) above their chronological age. Protocol Before 1992, two patients had subcutaneous leuprolide acetate 40 µg/kg/day once daily as initial treatment, and depot preparation of subcutaneous triptorelin or leuporelin 3.75 mg once a month was prescribed after 1992 when the depot form of GnRHa became available in Taiwan. Three factors including (1) bone age > 14 years, (2) growth velocity < 2 cm/year or (3) the family s satisfaction with the patient s height were considered when deciding on the appropriate time to stop GnRHa therapy. Patients height (measured with a stadiometer), weight and signs of puberty were evaluated once every 3 months. They underwent bone age study and pelvic sonography once every 6 months. Bone age was assessed according to Greulich and Pyle s criteria. 13 Predicted adult height (PAH) was calculated according to the method of Bayley and Pinneau. 14 GnRH test was done at 3 months, 1 year and then once every 6 months after GnRHa therapy. The uterine volumes were measured by the same technician. Uterine size, including its length, and largest anteroposterior and transverse diameters, was measured using ultrasonography, and uterine volume was estimated using the formula for a prolate ellipsoid. 15 GnRH stimulation test was performed with intravenous GnRH 0.1 mg, and serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels were measured at baseline, 30, 60, 90 and 120 minutes after GnRH stimulation. Adult height was measured when bone age exceeded 16 years and the growth rate was less than 0.5 cm per year. The adult height of these patients was measured at the age of 19.8 ± 2.0 years. We performed dual energy X-ray absorptiometry (DEXA) (Norland XR26; Norland Corp., Fort Atkinson, WI, USA) to determine vertebral BMD at L2 to L4 in these patients at least 2 years after completion of GnRHa therapy. J Formos Med Assoc 2007 Vol 106 No
3 Y.C. Tung, et al The data were compared with those of normal young Taiwanese adults in the Taipei region. Statistical analysis All auxological data are expressed as mean ± SD except the data in the figures. The grouping data were analyzed statistically using the Mann- Whitney U test. The paired data were compared by the Wilcoxon signed-rank test. A p value of less than 0.05 was considered statistically significant. Results Before treatment, serum FSH levels rose from 6.0 ± 2.9 miu/ml to 15.3 ± 0.8 miu/ml, and serum LH levels rose from 4.1 ± 3.4 miu/ml to 29.7 ± 23.5 miu/ml after GnRH stimulation. After GnRHa therapy for 3 months, the peak FSH and LH levels after GnRH stimulation were 2.0 ± 1.2 and 1.3 ± 1.5 miu/ml, respectively. As shown in Figure 1, the hypothalamus pituitary ovary axis was well suppressed during the period of GnRHa treatment. Pubertal response to GnRH test was observed within 6 months after the discontinuation of GnRHa therapy, and menstruation resumed 9.2 ± 5.9 months (range, 3 months to 2 years) after the discontinuation of therapy. Five patients had vaginal bleeding during the first month after therapy and eight patients had their breast regress to Tanner stage I after therapy. As shown in Figure 2, the uterine volume of the patients decreased from 9.7 ± 4.0 cm 3 to 4.3 ± 2.6 cm 3 after GnRHa therapy for 6 months (p < 0.01). Their uterine volume remained stationary during the period of therapy and it increased to Figure 1. Peak follicle-stimulating hormone (FSH) and luteinizing hormone (LH) responses to GnRH stimulation in patients with gonadotropindependent precocious puberty during the course of GnRHa therapy. p < 0.05 compared to the value at the start of therapy; p < 0.05 compared to the value at the end of therapy. End = time of discontinuation of GnRHa therapy; End = 6 months after the discontinuation of GnRHa therapy. Data are expressed as mean ± SEM. Peak gonadotropin level (miu/ml) FSH End End+0.5 LH Figure 2. Evolution of uterine size in patients with gonadotropin-dependent precocious puberty during the course of GnRHa therapy. p < 0.05 compared to the value at the start of therapy; p < 0.05 compared to the value at the end of therapy. End = time of discontinuation of GnRHa therapy; End = 6 months after the discontinuation of GnRHa therapy. Data are expressed as mean ± SEM. Uterine size (cm 3 ) End End J Formos Med Assoc 2007 Vol 106 No 10
4 GnRHa therapy in central precocious puberty 22.7 ± 7.4 cm 3 6 months after the discontinuation of GnRHa therapy. The target height of the patients in this study was ± 4.5 cm ( 0.5 ± 0.8 SD). They started GnRHa therapy at the age of 8.0 ± 1.5 years. As shown in Figure 3, the growth velocity was 7.3 ± 1.5 cm/year immediately before therapy, and decreased to 6.1 ± 1.5 cm/year at the first year, 3.9 ± 1.2 cm/year at the second year, and 3.2 ± 1.3 cm/year at the third year. As shown in Figure 4A, the progression of bone age was significantly decreased from 2.4 ± 1.4 years per year before therapy to 0.5 ± 0.7 years per year at the first year of therapy. Patients stopped GnRHa therapy at the age of 12.7 ± 0.9 years, with a bone age of 13.6 ± 0.6 years. At that time, their height was ± 5.0 cm. Bone age increased 1.1 ± 0.4 years at the first year after the discontinuation of GnRHa therapy. During the course of 4.7 ± 1.8 years of GnRHa therapy (range, years), their bone age increased 2.0 ± 1.6 years and their height gain was 19.0 ± 10.0 cm during the same period. Therefore, their adult height of ± 4.3 cm ( 0.6 ± 0.8 SD) was significantly higher than their PAH of ± 4.8 cm ( 2.3 ± 0.9 SD) at the start of therapy (p < 0.01), as shown in Figure 4B. Except for local discomfort at injection sites, there were no other serious adverse effects noted during the course of treatment. BMD was determined when the patients were 20.0 ± 1.9 years old, which was 7.3 ± 2.5 years after the discontinuation of GnRHa therapy. The BMD of their lumber spine was 0.99 ± 0.13 g/cm 3, which was 0.9 ± 1.0 SD (range, 2.4 to 0.8 SD) in comparison with the Growth velocity (cm/yr) Figure 3. Change in growth velocity during the course of GnRHa therapy. p < 0.05 compared to the value at the start of therapy; p < 0.05 compared to the value at the end of therapy. End = time of discontinuation of GnRHa therapy; End + 1 = 1 year after the discontinuation of GnRHa therapy. Data are expressed as mean ± SEM. 0 Before End End+1 A B Before End Adult height Bone age progression (yr) Predicted adult height (SDS) Before End End Figure 4. Changes in (A) bone age progression and (B) predicted adult height during the course of GnRHa therapy. p < 0.05 compared to the value at the start of therapy; p < 0.05 compared to the value at the end of therapy. End = time of discontinuation of GnRHa therapy; End + 1 = 1 year after the discontinuation of GnRHa therapy. Data are expressed as mean ± SEM. J Formos Med Assoc 2007 Vol 106 No
5 Y.C. Tung, et al data of normal young Taiwanese adults in the Taipei region. Five of the 11 patients (45%) had their BMD below 1 SD, which was defined as osteopenia. No correlation between BMD and duration of treatment was found. Discussion Our study showed that the activated hypothalamus pituitary ovary axis of patients with CPP was suppressed after 3 months of GnRHa therapy, and it remained well suppressed throughout the course of GnRHa therapy. In addition, the breast decreased in size and remained in prepubertal stage in most of the patients. Withdrawal bleeding was also observed during the first month after the start of GnRHa therapy in patients who had well-developed uterus. The uterine size of treated patients regressed rapidly within 6 months after therapy and remained stationary throughout the course of GnRHa therapy. All of these data reflect the fact that the hypothalamus pituitary ovary axis was effectively suppressed by GnRHa therapy. This study also demonstrated that the inappropriate progression of bone age maturation was slowed down by GnRHa therapy through a deprivation of estrogen effect by the suppression of the hypothalamus pituitary ovary axis in these patients. It was reported that the continuous growth of patients under GnRHa therapy can improve their adult height. 16 In this study, the bone age of the patients matured only 2 years during a course of 4.7 years of treatment, while they grew 19.0 cm during the same period of time. Thus, they had a mean adult height of cm ( 0.6 SD), which was close to their target height of cm ( 0.5 SD) and significantly taller than their PAH of cm ( 2.3 SD) at the start of GnRHa therapy. These results are consistent with previously reported data. 11,12,16,17 The reversibility of suppression of the hypothalamus pituitary ovary axis was also well demonstrated in our patients. Their serum gonadotropin levels showed a pubertal response to GnRH stimulation and their uterine size enlarged within 6 months after the discontinuation of GnRHa therapy. All experienced resumption of menstrual flow within 2 years after the discontinuation of GnRHa therapy. Such findings are consistent with a previous report. 9 The introduction of long-acting depot preparations of GnRHa has improved patient compliance due to the advantage of a reduced frequency of injection, which is one of the important factors that makes long-term compliance to suppressive therapy possible. 5,18,19 Except for local pain at the injection sites, no other serious adverse effects were detected in our patients during the period of GnRHa therapy. Bone mineral accretion is a complex process and estrogen may play an important role in it GnRHa therapy suppresses the hypothalamus pituitary ovary axis, which theoretically may decrease the accretion of bone mass, resulting in osteopenia or osteoporosis. Forty-five percent of the patients in this study had osteopenia in contrast to previous reports where no significant change in BMD was observed after GnRHa therapy. 11,23 On the other hand, Heger et al reported that the lumbar spine BMD of CPP patients treated with GnRHa was not significantly different from that of control subjects, but they noticed that 15% of their patients had osteopenia. 12 Yanovski et al also reported that 82% of their patients treated with GnRHa had BMD more than 1 SD below the population. 24 Further studies are indicated to clarify such a discrepancy. Studies on the prevention of low BMD in CPP patients treated with GnRHa have rarely been reported. Antoniazzi et al found that the BMD in CPP patients treated with GnRHa and calcium supplementation was better preserved than the BMD of CPP patients not given calcium supplementation. 23 Further studies are necessary to confirm this. In conclusion, GnRHa therapy can effectively suppress the prematurely activated hypothalamus pituitary ovary axis and improve the adult height of patients with gonadotropin-dependent precocious puberty. However, reduced BMD is a possible major side effect that should be seriously considered during long-term GnRHa therapy. 830 J Formos Med Assoc 2007 Vol 106 No 10
6 GnRHa therapy in central precocious puberty References 1. Bridges NA, Christopher JA, Hindmarsh PC, et al. Sexual precocity: sex incidence and etiology. Arch Dis Child 1994;70: Dattani MT, Hindmarch PC. Normal and abnormal puberty. In: Brook C, Clayton P, Brown R, eds. Clinical Pediatric Endocrinology, 5 th edition. London: Blackwell Science, 2005: Sigurjonsdottir TJ, Hayles AB. Precocious puberty. Am J Dis Child 1968;115: Crowley WF, Comite F, Vale W, et al. Therapeutic use of pituitary desensitization with a long-acting agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab 1981;52: Cornea A, Janovick JA, Maya-Nunez G, et al. Gonadotropinreleasing hormone receptor microaggregation. Rate monitored by fluorescence resonance energy transfer. J Biol Chem 2001;276: Kaplan SL, Grumbach MM. Clinical Review 14: pathophysiology and treatment of sexual precocity. J Clin Endocrinol Metab 1990;71: Heger S, Sippell WG, Partsch CJ. Gonadotropin-releasing hormone analogue treatment for precocious puberty: twenty years of experience. Endocr Dev 2005;8: Tonini G, Lazzerini M. Side effects of GnRH analogue treatment in childhood. J Pediatr Endocrinol Metab 2000; 13(Suppl 1): Manasco PK, Pescovitz OH, Feuillan PP, et al. Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty. J Clin Endocrinol Metab 1988;67: Paterson WF, McNeil E, Young D, et al. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty. Clin Endocrinol 2004;61: Bertelloni S, Baroncelli GI, Sorrentino MC, et al. Effect of central precocious puberty and gonadotropinreleasing hormone analogue treatment on peak bone mass and final height in females. Eur J Pediatr 1998; 157: Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab 1999;84: Greulich WW, Pyle SI. Radiographic Atlas of Skeletal Development of Hand and Wrist, 2 nd edition. Stanford: Stanford University Press, Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich Pyle hand standards. J Pediatr 1952;40:423 41/41: Chen SU, Tsai WY, Lee CN, et al. Uterine and ovarian dimensions in normal Taiwanese prepubertal and postpubertal girls: an ultrasonographic study. J Med Ultrasound 1993;2: Klein KO, Barnes KM, Jones JV, et al. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Heath experience. J Clin Endocrinol Metab 2001;86: Adan L, Chemaitilly W, Trivin C, et al. Factors predicting adult height in girls with idiopathic central precocious puberty: implications for treatment. Clin Endocrinol 2002; 56: Boepple PA, Mansfield MJ, Wierman ME, et al. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty. Endocr Rev 1986;7: Roger M, Chaussain JL, Berlier P, et al. Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6- luteinizing hormone-releasing hormone microcapsules. J Clin Endocrinol Metab 1986;62: Gilsanz V, Roe TF, Mora S, et al. Changes in vertebral bone density in black girls and white girls during childhood and puberty. N Engl J Med 1991;325: Heaney RP, Abrams S, Dawson-Hughes B, et al. Peak bone mass. Osteoporos Int 2000;11: Matkovic V, Jelic T, Wardlaw GM, et al. Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis: inference from a crosssectional model. J Clin Invest 1994;93: Antoniazzi F, Zamboni G, Bertoldo F, et al. Bone mass at final height in precocious puberty after gonadotropinreleasing hormone agonist with and without calcium supplementation. J Clin Endocrinol Metab 2003;88: Yanovski JA, Rose SR, Municchi G, et al. Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N Engl J Med 2003;348: J Formos Med Assoc 2007 Vol 106 No
Zohreh Karamizadeh, MD; Anis Amirhakimi*, MD; Gholamhossein Amirhakimi, MD
Original Article Iran J Pediatr Jun 2014; Vol 24 (No 3), Pp: 293-299 Effect of Pubertal Suppression on Linear Growth and Body Mass Index; a Two-Year Follow-Up in Girls with Genetic Short Stature and Rapidly
More information2.0 Synopsis. Lupron Depot M Clinical Study Report R&D/09/093. (For National Authority Use Only) to Part of Dossier: Name of Study Drug:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: Name of Study Drug: Volume: Abbott-43818 (ABT-818) leuprolide acetate for depot suspension (Lupron Depot ) Name of
More informationEffect of Growth Hormone Therapy on Adult Height of Children with Turner Syndrome
ORIGINAL ARTICLE Effect of Growth Hormone Therapy on Adult Height of Children with Turner Syndrome Ping-Yi Hsu, Yi-Ching Tung, Wen-Yu Tsai,* Jing-Sheng Lee, Pei-Hung Hsiao Background/Purpose: Short stature
More informationLong-Term Experience with GnRH Agonist Treatment of Central Precocious Puberty
Clin Pediatr Endocrinol 1993; (Supp13):49-56 Copyright (C)1993 by The Japanese Society for Pediatric Endocrinology Long-Term Experience with GnRH Agonist Treatment of Central Precocious Puberty Paul A.
More informationRole of surgical resection in the treatment of hypothalamic hamartomas causing precocious puberty Report of six cases
Role of surgical resection in the treatment of hypothalamic hamartomas causing precocious puberty Report of six cases Laura Stewart, M.D., F.R.C.P.(C), Paul Steinbok, M.B.B.S., F.R.C.S.(C), and Jorge Daaboul,
More informationTreatment outcomes of gonadotropin-releasing hormone agonist in obese girls with central precocious puberty
Original article https://doi.org/10.6065/apem.2017.22.4.259 Ann Pediatr ocrinol Metab 2017;22:259-265 Treatment outcomes of gonadotropin-releasing hormone agonist in obese girls with central precocious
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationPedsCases Podcast Scripts
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on Puberty and Pubertal Disorders Part 2: Precocious Puberty. These podcasts are designed to give medical students an overview
More informationHHS Public Access Author manuscript Endocr Pract. Author manuscript; available in PMC 2017 March 09.
BIRD S-EYE VIEW OF GnRH ANALOG USE IN A PEDIATRIC ENDOCRINOLOGY REFERRAL CENTER Sara E. Watson, MD, MS 1, Ariana Greene, BS 1, Katherine Lewis, MD, MS 2, and Erica A. Eugster, MD 1 1 Section of Endocrinology
More informationCorrelation of Serum Follicular Stimulating Hormone
Correlation of Serum Follicular Stimulating Hormone (FSH) and Luteinizing Hornone (LH) as Measured by Radioimmunoassay in Disorders of Sexual Development ROBERT PENNY, HARVEY J. GUYDA, ALIcE BAGHDASSARIAN,
More informationIdiopathic central precocious puberty associated with an enlarged pituitary gland
Idiopathic central precocious puberty associated with an enlarged pituitary gland Idiopathic central precocious puberty associated with an enlarged pituitary gland S Pathmanathan 1, Navoda Atapattu 2,
More informationClinical Study Evaluating the Efficacy of Treatment with a GnRH Analogue in Patients with Central Precocious Puberty
International Endocrinology Volume 2015, Article ID 247386, 7 pages http://dx.doi.org/10.1155/2015/247386 Clinical Study Evaluating the Efficacy of Treatment with a GnRH Analogue in Patients with Central
More informationGonadotropin-releasing hormone (GnRH) analog depot preparations have now been in use for more than 15 years and
REPRODUCTIVE OUTCOME IN PATIENTS TREATED AND NOT TREATED FOR IDIOPATHIC EARLY PUBERTY: LONG-TERM RESULTS OF A RANDOMIZED TRIAL IN ADULTS ALESSANDRA CASSIO, MD, MILVA O. BAL, MD, LUIGI F. ORSINI, MD, ANTONIO
More informationEffect of letrozole on the predicted adult height in boys with constitutional delay of growth and puberty: A clinical trial.
Biomedical Research 2017; 28 (15): 6813-6817 ISSN 0970-938X www.biomedres.info Effect of letrozole on the predicted adult height in boys with constitutional delay of growth and puberty: A clinical trial.
More informationKJLM. Gonadotropin-releasing Hormone Stimulation Test for Precocious Puberty INTRODUCTION. Original Article Clinical Chemistry
Korean J Lab Med 2011;31:244-249 Original Article Clinical Chemistry Gonadotropin-releasing Hormone Stimulation Test for Precocious Puberty Han Kyul Kim, M.D. 1, Seung Jung Kee, M.D. 2, Ji Yeon Seo, M.D.
More informationand LHRH Analog Treatment in
Endocrine Journal 1996, 43 (Suppl), S13-S17 Combined GH Short Children and LHRH Analog Treatment in TosHIAKI TANAKA***, MARL SATOH**, AND ITSURo HIBI* *Division of Endocrinology & Metabolism, National
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationA single sample GnRHa stimulation test in the diagnosis of precocious puberty
Yazdani et al. International Journal of Pediatric Endocrinology 212, 212:23 RESEARCH Open Access A single sample GnRHa stimulation test in the diagnosis of precocious puberty Parvin Yazdani 1*, Yuezhen
More informationLaura Stewart, MD, FRCPC Clinical Associate Professor Division of Pediatric Endocrinology University of British Columbia
Precocious Puberty Laura Stewart, MD, FRCPC Clinical Associate Professor Division of Pediatric Endocrinology University of British Columbia Faculty Disclosure Faculty: Laura Stewart No relationships with
More informationEtiologies of Precocious Puberty: 15-Year Experience in a Tertiary Hospital in Southern Thailand
Freund Publishing House Ltd., London Journal of Pediatric Endocrinology & Metabolism, 23, 1263-1271 (2010) Etiologies of Precocious Puberty: 15-Year Experience in a Tertiary Hospital in Southern Thailand
More informationLumbar spine and proximal femur BMD values in Turkish girls and the
Lumbar spine and proximal femur and the effect of precocious puberty on BMD. Ersoy Kekilli 1, Mustafa Arif Aluçlu 1, Fatih Batı 1, İsmail Köksal 1 1 Inonu University, Medical Faculty, Department of Nuclear
More informationAccepted 13 July, 2011
Journal of Medicine and Medical Science Vol. 2(7) pp. 955-960, July 2011 Available online@ http://www.interesjournals.org/jmms Copyright 2011 International Research Journals Full Length Research Paper
More informationPrecocious Puberty. Disclosures. No financial disclosures 2/28/2019
Precocious Puberty Bracha Goldsweig, MD Pediatric Endocrinologist Children s Hospital and Medical Center, Omaha, NE University of Nebraska Medical Center Disclosures No financial disclosures 1 Objectives
More informationThree-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty
European Journal of Endocrinology (2006) 154 119 124 ISSN 0804-4643 CLINICAL STUDY Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty Jean-Claude Carel,
More informationEndocrine Pharmacology
Endocrine Pharmacology 17-2-2013 DRUGS AFFECTING THE ENDOCRINE SYSTEM The endocrine system is the system of glands, each of which secretes a type of hormone directly into the bloodstream to regulate the
More informationSomatostatin Analog and Estrogen Treatment in a Tall Girl
Clin Pediatr Endocrinol 1995; 4 (2): 163-167 Copyright (C) 1995 by The Japanese Society for Pediatric Endocrinology Somatostatin Analog and Estrogen Treatment in a Tall Girl Toshiaki Tanaka, Mari Satoh,
More informationClinical Guideline ADRENARCHE MANAGEMENT OF CHILDREN PRESENTING WITH SIGNS OF EARLY ONSET PUBIC HAIR/BODY ODOUR/ACNE
Clinical Guideline ADRENARCHE MANAGEMENT OF CHILDREN PRESENTING WITH SIGNS OF EARLY ONSET PUBIC HAIR/BODY ODOUR/ACNE Includes guidance for the distinction between adrenarche, precocious puberty and other
More informationWhy is my body not changing? Conflicts of interest. Overview 11/9/2015. None
Why is my body not changing? Murthy Korada Pediatrician, Pediatric Endocrinologist Ridge Meadows Hospital Surrey Memorial Hospital None Conflicts of interest Overview Overview of normal pubertal timing
More informationCASE 41. What is the pathophysiologic cause of her amenorrhea? Which cells in the ovary secrete estrogen?
CASE 41 A 19-year-old woman presents to her gynecologist with complaints of not having had a period for 6 months. She reports having normal periods since menarche at age 12. She denies sexual activity,
More informationEndocrine: Precocious Puberty Health care guidelines for Spina Bifida
Endocrine: Precocious Puberty Health care guidelines for Spina Bifida Precocious Puberty Primary outcome: Timely assessment, identification, appropriate referral, and management of precocious puberty.
More information3 year old boy with puberty. Katie Stanley, MD August 1, 2013
3 year old boy with puberty Katie Stanley, MD August 1, 2013 Initial presentation 3 and 11/12 year old boy with signs of puberty Presented to outside endocrinologist in 2002 with: Pubic hair since 2.5
More informationSHARED CARE PRESCRIBING GUIDELINE Triptorelin (Gonapeptyl Depot 3.75 mg TM, Decapeptyl SR mg TM ) for precocious puberty
WORKING IN PARTNERSHIP WITH SHARED CARE PRESCRIBING GUIDELINE Triptorelin (Gonapeptyl Depot 3.75 mg TM, Decapeptyl SR 11.25 mg TM ) for precocious puberty NHS Surrey s Medicines Management Committee classification:
More informationHormonal Control of Human Reproduction
Hormonal Control of Human Reproduction Bởi: OpenStaxCollege The human male and female reproductive cycles are controlled by the interaction of hormones from the hypothalamus and anterior pituitary with
More informationChapter 4. Managing Fertility in Childhood Cancer Patients T.K. Woodruff and K.A. Snyder (eds.) Oncofertility. Springer 2007
Chapter 4 Managing Fertility in Childhood Cancer Patients T.K. Woodruff and K.A. Snyder (eds.) Oncofertility. Springer 2007 The original publication of this article is available at www.springerlink.com
More informationPuberty and Pubertal Disorders Part 3: Delayed Puberty
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on Puberty and Pubertal Disorders Part 3: Delayed Puberty These podcasts are designed to give medical students an overview
More informationFactors that predict a positive response on gonadotropin-releasing hormone stimulation test for diagnosing central precocious puberty in girls
Original article http://dx.doi.org/10.6065/apem.2013.18.4.202 Ann Pediatr Endocrinol Metab 2013;18:202-207 Factors that predict a positive response on gonadotropin-releasing hormone stimulation test for
More informationAssisted Reproductive Technology (ART) / Infertility / Synarel (nafarelin)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.03 Subject: Synarel Page: 1 of 5 Last Review Date: September 15, 2016 Synarel Description Assisted
More informationTower Hamlets GPs and Barts Health NHS Trust Shared Care Guidelines. TRIPTORELIN Central Precocious Puberty. Patient Name : Date of Birth: NHS No:
DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AND FILED IN NOTES Patient Name : Date of Birth: NHS No: Name of Referring Consultant: Contact number: INTRODUCTION Indication and Licensing Gonadotrophin
More informationLeuteinizing hormone responses to leuprolide acetate discriminate between hypogonadotropic hypogonadism and constitutional delay of puberty
FERTILITY AND STERILITY VOL. 77, NO. 3, MARCH 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Leuteinizing hormone
More informationPrecocious puberty and statural growth
Human Reproduction Update, Vol.10, No.2 pp. 135±147, 2004 DOI: 10.1093/humupd/dmh012 Precocious puberty and statural growth Jean-Claude Carel 1,4, Najiba Lahlou 2,3, Marc Roger 3 and Jean Louis Chaussain
More informationUltrasound Assessment of Breast Development: Distinction Between Premature Thelarche and Precocious Puberty
Pediatric Imaging Original Research Youn et al. Ultrasound Assessment of Breast Development Pediatric Imaging Original Research Inyoung Youn 1 Sung Hee Park 2 In Seok Lim 3 Soo Jin Kim 2 Youn I, Park SH,
More informationMale patients presenting with rapidly progressive puberty associated with malignant tumors
Case report http://dx.doi.org/10.6065/apem.2016.21.1.51 Ann Pediatr Endocrinol Metab 2016;21:51-55 Male patients presenting with rapidly progressive puberty associated with malignant tumors Soo Jung Kim,
More informationBone Development. V. Gilsanz and O. Ratib, Hand Bone Age, DOI / _2, Springer-Verlag Berlin Heidelberg 2012
Bone Development 2 Skeletal maturity is a measure of development incorporating the size, shape and degree of mineralization of bone to define its proximity to full maturity. The assessment of skeletal
More informationGrowth Hormone plus Childhood Low- Dose Estrogen in Turner s Syndrome. N Engl J Med 2011;364: Present by R5 郭恬妮
Growth Hormone plus Childhood Low- Dose Estrogen in Turner s Syndrome N Engl J Med 2011;364:1230-42. Present by R5 郭恬妮 Introduction Turner s syndrome : partial or complete X-chromosome monosomy, 1 in 2000
More informationOBJECTIVES. Rebecca McEachern, MD. Puberty: Too early, Too Late or Just Right? Special Acknowledgements. Maryann Johnson M.Ed.
1 Puberty: Too early, Too Late or Just Right? Maryann Johnson M.Ed., BSN, RN Special Acknowledgements Rebecca McEachern, MD OBJECTIVES Illustrate basic endocrine system and hormonal pathways Define the
More informationGrowth hormone therapy in a girl with Turner syndrome showing a large increase over the initially predicted ht of 4 5
Disorders of Growth and Puberty: How to Recognize the Normal Variants vs Patients Who Need to be Evaluated Paul Kaplowitz, M.D Pediatric Endocrinology. VCU School of Medicine Interpretation of Growth Charts
More informationRequest for Prior Authorization Growth Hormone (Norditropin
Request for Prior Authorization Growth Hormone (Norditropin, Nutropin/AQ ) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Growth Hormone require a
More informationDose Effects of Growth Hormone during Puberty
Puberty Horm Res 2003;60(suppl 1):52 57 DOI: 10.1159/000071226 Dose Effects of Growth Hormone during Puberty Paul Saenger Department of Pediatrics, Division of Pediatric Endocrinology, Childrens Hospital
More informationV. CALCATERRA*, P. SAMPAOLO, C. KLERSY, D. LARIZZA*, A. ALFEI, V. BRIZZI*, F. BENEVENTI and M. CISTERNINO*
Ultrasound Obstet Gynecol 2009; 33: 85 91 Published online 11 December 2008 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/uog.6271 Utility of breast ultrasonography in the diagnostic
More informationand Luteinizing Hormone as Measured by Radioimmunoassay Correlated with Sexual Development in Hypopituitary Subjects
Serum Follicular - Stimulating Hormone and Luteinizing Hormone as Measured by Radioimmunoassay Correlated with Sexual Development in Hypopituitary Subjects ROBERT PENNY, THOMAS P. FOLEY, JR., and ROBERT
More informationPUBERTY. Preetha Krishnamoorthy. Division of Pediatric Endocrinology
PUBERTY Preetha Krishnamoorthy Division of Pediatric Endocrinology Case 1 8-year-old girl referred for breast development noted by mom What do you want to know? Normal or abnormal? What if this was an
More informationTreatment with a Luteinizing Hormone Releasing Hormone Agonist in Adolescents with Short Stature
The new england journal of medicine original article Treatment with a Luteinizing Hormone Releasing Hormone Agonist in Adolescents with Short Stature Jack A. Yanovski, M.D., Ph.D., Susan R. Rose, M.D.,
More informationManagement and outcome of central precocious puberty
Clinical Endocrinology (2002) 56, 129 148 Blackwell Review Science Ltd Treatment of precocious puberty Management and outcome of central precocious puberty Carl-Joachim Partsch, Sabine Heger and Wolfgang
More informationThe Adolescent: A Patient at Risk: Ovarian Failure in Adolescent Cancer Survivors
The Adolescent: A Patient at Risk: Ovarian Failure in Adolescent Cancer Survivors Avner Hershlag MD Professor and Chief Center for Human Reproduction North Shore LIJ Hofsra university School of Medicine
More informationTrelstar (triptorelin) (Intramuscular)
Trelstar (triptorelin) (Intramuscular) Last Review Date: 02/06/2018 Date of Origin: 11/28/2011 Document Number: IC-0131 Dates Reviewed: 12/2011, 03/2012, 06/19/2012, 09/2012, 12/2012, 03/2013, 06/2013,
More informationTrelstar Depot (triptorelin)
Dates Reviewed: 12/13/2011, 03/2012, 06/19/2012, 09/06/2012, 12/06/2012, 03/07/2013, 06/06/2013, Date of Origin: 11/28/2011 09/05/2013, 12/05/2013, 03/25/2014 Prior Auth Available: Post-service edit: The
More informationKENJI OHYAMA, MASANORI OHTA, YosHIKo NAKAGOMI, YOSHIE SHIMURA, T0M0AKI SANG, KAZUMASA SATO, SHINPEI NAKAZAWA, AND HIROMICHI ISHIKAWA*
Endocrine Journal 1997, 44 (4), 459-465 Restoration of Seminiferous Tubular Function after Discontinuation of Long-Term Gonadotropin-Releasing Hormone Agonist Administration in Premature Male Rats KENJI
More informationCY Tse, AMK Chow, SCS Chan. Introduction
Effects of an extended-interval dosing regimen of triptorelin depot on the hormonal profile of patients with endometriosis: prospective observational study CY Tse, AMK Chow, SCS Chan Objective. To evaluate
More informationFINAL HEIGHT IN GIRLS WITH CENTRAL IDIOPATHIC PRECOCIOUS PUBERTY. TREATED WITH GnRH ANALOGUE AND OXANDROLONE
J Clin Endocrin Metab. First published January 31, 2006 as doi:10.1210/jc.2005-1693 FINAL HEIGHT IN GIRLS WITH CENTRAL IDIOPATHIC PRECOCIOUS PUBERTY TREATED WITH GnRH ANALOGUE AND OXANDROLONE Alessandra
More informationReproductive physiology
Reproductive physiology Sex hormones: Androgens Estrogens Gestagens Learning objectives 86 (also 90) Sex Genetic sex Gonadal sex Phenotypic sex XY - XX chromosomes testes - ovaries external features Tha
More informationREPRODUCTION & GENETICS. Hormones
REPRODUCTION & GENETICS Hormones http://www.youtube.com/watch?v=np0wfu_mgzo Objectives 2 Define what hormones are; Compare and contrast the male and female hormones; Explain what each hormone in the mail
More information2-year-old girl with premature thelarche. Endorama February 5, 2015 Carmen Mironovici, M.D.
2-year-old girl with premature thelarche Endorama February 5, 2015 Carmen Mironovici, M.D. Chief complaint Premature thelarche first noted at 21 months of age Patient referred to Endocrinology Clinic for
More information1. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Eligard Trelstar - Vantas (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationFollow-up Study of Adolescent Girls With a History of Premature Pubarche
JOURNAL OF ADOLESCENT HEALTH 1996;18:301-305 ADOLESCENT HEALTH BRIEF/FELLOWSHIP FORUM Follow-up Study of Adolescent Girls With a History of Premature Pubarche DAPHNE MILLER, M.D., S. JEAN EMANS, M.D.,
More informationBirth weight influences long-term catch-up growth and height prognosis of GH-deficient children treated before the age of 2 years
European Journal of Endocrinology (2000) 142 460 465 ISSN 0804-4643 CLINICAL STUDY Birth weight influences long-term catch-up growth and height prognosis of GH-deficient children treated before the age
More information10.7 The Reproductive Hormones
10.7 The Reproductive Hormones December 10, 2013. Website survey?? QUESTION: Who is more complicated: men or women? The Female Reproductive System ovaries: produce gametes (eggs) produce estrogen (steroid
More informationReproductive Health and Pituitary Disease
Reproductive Health and Pituitary Disease Janet F. McLaren, MD Assistant Professor Division of Reproductive Endocrinology and Infertility Department of Obstetrics and Gynecology jmclaren@uabmc.edu Objectives
More informationEndocrine Late Effects in Survivors of Pediatric SCT
Endocrine Late Effects in Survivors of Pediatric SCT Daphna Hutt Pediatric Hem-Onc & BMT Sheba Medical Center, Israel #EBMT2015 www.ebmt.org Stiller CA (2007). Childhood Cancer In Britain. Oxford University
More informationGrowth and Puberty: A clinical approach. Dr Esko Wiltshire
Growth and Puberty: A clinical approach Dr Esko Wiltshire NOTHING TO DISCLOSE Why is this character short? Food Psychosocial factors Major Systems (+drugs) Genetic potential Perinatal Classical Hormones
More informationReproductive FSH. Analyte Information
Reproductive FSH Analyte Information 1 Follicle-stimulating hormone Introduction Follicle-stimulating hormone (FSH, also known as follitropin) is a glycoprotein hormone secreted by the anterior pituitary
More information1. During the follicular phase of the ovarian cycle, the hypothalamus releases GnRH.
1. During the follicular phase of the ovarian cycle, the hypothalamus releases GnRH. 2. This causes the anterior pituitary to secrete small quantities of FSH and LH. 3. At this time, the follicles in the
More informationEvaluation of central precocious puberty treatment with GnRH analogue at the Triangulo Mineiro Federal University (UFTM)
original article Evaluation of central precocious puberty treatment with GnRH analogue at the Triangulo Mineiro Federal University (UFTM) Maria de Fátima Borges 1, Priscila de Melo Franciscon 1, Thamy
More informationOvarian and Uterine Findings in Pelvic Sonography
Article Ovarian and Uterine Findings in Pelvic Sonography Comparison Between Prepubertal Girls, Girls With Isolated Thelarche, and Girls With Central Precocious Puberty Liliane Diefenthaeler Herter, PhD,
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationUse of Ovarian Suppression and Ablation in Breast Cancer Treatment
Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Dr Marina Parton Consultant Medical Oncologist Royal Marsden and Kingston Hospitals Overview Breast cancer phenotypes Use of ovarian manipulation
More information9.4 Regulating the Reproductive System
9.4 Regulating the Reproductive System The Reproductive System to unite a single reproductive cell from a female with a single reproductive cell from a male Both male and female reproductive systems include
More information2. Does the member have a diagnosis of central precocious puberty? Y N
Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Leuprolide (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationA Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis
SH SUEN & SCS CHAN A Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis Sik Hung SUEN MBChB, MRCOG Resident
More informationPFIZER INC. Study Centre: One centre from Hungary enrolled subjects in this study
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationGrowth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka
Growth hormone therapy for short stature in adolescents Growth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka K K K Gamage,
More informationI. Endocrine System & Hormones Figure 1: Human Endocrine System
I. Endocrine System & Hormones Figure 1: Human Endocrine System Endocrine System: a) Endocrine glands are ductless since they lack specific vessels for the transport of hormones throughout the body. Instead,
More informationFemale Gonadal Toxicity Surveillance Harmonization: Formulation of Recommendations
Female Gonadal Toxicity Surveillance Harmonization: Formulation of Recommendations Chair: Riccardo Haupt (I) Hamish Wallace (UK) Coordinator: Wendy van Dorp (NL) Guideline KNOWLEDGE/ EVIDENCE RECOMMENDATION
More informationThe reproductive system
The reproductive system THE OVARIAN CYCLE HORMONAL REGULATION OF OOGENSIS AND OVULATION hypothalamic-pituitary-ovary axis Overview of the structures of the endocrine system Principal functions of the
More informationOSTEOPOROSIS IS A very common metabolic disorder
0013-7227/02/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 87(1):84 89 Printed in U.S.A. Copyright 2002 by The Endocrine Society Effects of Treatment with GH Alone or in Combination with
More informationPrecocious Puberty (Complete, Partial)
The Prepubertal Girl Sultan C (ed): Pediatric and Adolescent Gynecology. Evidence-Based Clinical Practice. Endocr Dev. Basel, Karger, 2004, vol 7, pp 57 65 Precocious Puberty (Complete, Partial) R. Stanhope,
More informationInvestigation: The Human Menstrual Cycle Research Question: How do hormones control the menstrual cycle?
Investigation: The Human Menstrual Cycle Research Question: How do hormones control the menstrual cycle? Introduction: The menstrual cycle (changes within the uterus) is an approximately 28-day cycle that
More informationSupplemental Data: Detailed Characteristics of Patients with MKRN3. Patient 1 was born after an uneventful pregnancy. She presented in our
1 2 Supplemental Data: Detailed Characteristics of Patients with MKRN3 Mutations 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Patient 1 was born after an uneventful pregnancy. She presented
More informationTwenty-four Hour Plasma GH, FSH and LH Profiles in Patients with Turner's Syndrome
Twenty-four Hour Plasma GH, FSH and LH Profiles in Patients with Turner's Syndrome MARIA CORAZON R. VILLADOLID, KAZUE TAKANO, NAOMI HIZUKA, KUMIKO ASAKAWA, IZUMI SUKEGAWA, REIKO HORIKAWA AND KAZUO SHIZUME
More informationOriginal article. Introduction
Original article http://dx.doi.org/10.6065/apem.2014.19.3.135 Ann Pediatr Endocrinol Metab 2014;19:135-140 Significant adverse reactions to long-acting gonadotropin-releasing hormone agonists for the treatment
More informationPERIPHERAL PRECOCIOUS PUBERTY SECONDARY TO MCCUNE-AL BRIGHT SYNDROME
CASE REPORT PERIPHERAL PRECOCIOUS PUBERTY SECONDARY TO MCCUNE-AL BRIGHT SYNDROME Suhaimi H 1, Fatimah Harun 2, Mohd Yazid Jalaluddin 2 1. Department of Paediatrics, School of Medical Sciences, Universiti
More informationImaging in Pediatric and Adolescent Gynecology
Background and Tools Sultan C (ed): Pediatric and Adolescent Gynecology. Evidence-Based Clinical Practice. Endocr Dev. Basel, Karger, 2004, vol 7, pp 9 22 Imaging in Pediatric and Adolescent Gynecology
More informationfor months until the diagnosis were confirmed 86 were IHH and the other 47 were CDP. Repeated triptorelin stimulating tests were conducted in 9
ACTA ACADEMIAE MEDICINAE SINICAE 100730 010-65295073 wsheyan@vip.sina.com LHRH IHH CDP 133 IHH 86 CDP 47 14 24 ~ 48 9 IHH 13 CDP 1 - - LH LH IHH CDP IHH LH 1. 9 ± 1. 2 U /L CDP LH 13. 7 ± 8. 3 U /L P
More informationLong term outcomes of the treatment of central precocious puberty
Page 1 of 21 Accepted Preprint first posted on 14 October 2015 as Manuscript EJE-15-0590 1 Long term outcomes of the treatment of central precocious puberty 2 3 Federica Guaraldi 1, Guglielmo Beccuti 1,
More informationAdrenarche and Skeletal Maturation during Luteinizing Hormone Releasing Hormone Analogue Suppression of Gonadarche
Adrenarche and Skeletal Maturation during Luteinizing Hormone Releasing Hormone Analogue Suppression of Gonadarche Margaret E. Wierman, Donna E. Beardsworth, John D. Crawford, John F. Crigler, Jr., M.
More informationPuberty and Pubertal Disorders. Lisa Swartz Topor, MD, MMSc Pediatric Endocrinology July 2018
Puberty and Pubertal Disorders Lisa Swartz Topor, MD, MMSc Pediatric Endocrinology July 2018 Objectives Review normal pubertal development Recognize common pubertal disorders Identify recent trends in
More informationChapter 28: REPRODUCTIVE SYSTEM: MALE
Chapter 28: REPRODUCTIVE SYSTEM: MALE I. FUNCTIONAL ANATOMY (Fig. 28.1) A. Testes: glands which produce male gametes, as well as glands producing testosterone 2. Seminiferous tubules (Fig.28.3; 28.5) a.
More information10/16/2014. Adolescents (ages 10 19) and young adults (ages 20 24) together compose about 21% of the population of the United States.
The purview of pediatrics includes the growth, development, and health of the child and therefore begins in the period before birth when conception is apparent. It continues through childhood and adolescence
More informationChapter 14 Reproduction Review Assignment
Date: Mark: _/45 Chapter 14 Reproduction Review Assignment Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Use the diagram above to answer the next question.
More informationPrecocious Puberty. Dr. Abdulmoein Eid Al-Agha Consultant, Pediatric Endocrinologist, King Abdul Aziz University Hospital, Jeddah, Saudi Arabia
Precocious Puberty Dr. Abdulmoein Eid Al-Agha Consultant, Pediatric Endocrinologist, King Abdul Aziz University Hospital, Jeddah, Saudi Arabia Discussion points When to say this child is having Precocious
More informationFemale Reproductive System. Lesson 10
Female Reproductive System Lesson 10 Learning Goals 1. What are the five hormones involved in the female reproductive system? 2. Understand the four phases of the menstrual cycle. Human Reproductive System
More information